Technical transformation of biodefense vaccines

Vaccine

Volumn 27, Issue SUPPL. 4, 2009, Pages D8-

  Lu, Shan ^a   Wang, Shixia ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Biodefense; Vaccine

Indexed keywords

ANTHRAX VACCINE; BACTERIAL VACCINE; BLUETONGUE VACCINE; CLOSTRIDIUM BOTULINUM VACCINE; DNA VACCINE; EBOLA VACCINE; FOOT AND MOUTH DISEASE VACCINE; FRANCISELLA TULARENSIS VACCINE; HANTAVIRUS VACCINE; INFLUENZA VACCINE; MARBURG VIRUS VACCINE; RICKETTSIA VACCINE; RIFT VALLEY FEVER VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINE; VENEZUELAN EQUINE ENCEPHALITIS VACCINE; VIRUS VACCINE; YERSINIA PESTIS VACCINE;

ANTHRAX; ARTICLE; BIOLOGICAL WARFARE; BLUETONGUE; BOTULISM; EBOLA HEMORRHAGIC FEVER; FOOT AND MOUTH DISEASE; HANTAVIRUS INFECTION; HUMAN; IMMUNE RESPONSE; INFLUENZA; MARBURG HEMORRHAGIC FEVER; NONHUMAN; PLAGUE; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; RICKETTSIACEAE INFECTION; RIFT VALLEY FEVER; SMALLPOX; TULAREMIA; VACCINATION; VENEZUELAN EQUINE ENCEPHALITIS;

EID: 79952228520     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.055     Document Type: Article

References (142)

1. Henderson DA, Borio LL, Grabenstein JD. Smallpox and vaccinia. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. fifth ed. Elservier; 2008. p. 773-804.
2. Mora LF, Khan AH, Sperling LS. Cardiac complications after smallpox vaccination. Southern Medical Journal 2009;(May).
3. Cassimatis DC, Atwood JE, Engler RM, Linz PE, Grabenstein JD, Vernalis MN. Smallpox vaccination and myopericarditis: a clinical review. Journal of the American College of Cardiology 2004;43(May (9)):1503-10.
4. Kennedy JS, Co M, Green S, Longtine K, Longtine J, O'Neill MA, et al. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 2008;26(August (35)):4420-4.
5. U.S. Center for Disease Control and Prevention (CDC). Withdrawal of rotavirus vaccine recommendation. MMWR 1999;48(Nov(43)):1007.
6. Kingsbury N. Anthrax vaccine: changes to manufacturing process. US GAO Testimony 2001;GAO-02-181T.
7. Greenberg RN, Kennedy JS. ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opinion on Investigational Drugs 2008;17(April (4)):555-64.
8. Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, et al. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine 2006;24(August (33-34)):5950-9.
9. Lu D, Hickey AJ. Pulmonary vaccine delivery. Expert Review of Vaccines 2007;6(April (2)):213-26.
10. Uddowla S, Freytag LC, Clements JD. Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens. Vaccine 2007;25(November (47)):7984-93.
11. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proceedings of the National Academy of Sciences of the United States of America 2000;97(May (11)):6108-13.
12. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, et al. Generation of influenza A viruses entirely from cloned cDNAs. Proceedings of the National Academy of Sciences of the United States of America 1999;96(August (16)):9345-50.
13. Parent MA, Berggren KN, Kummer LW, Wilhelm LB, Szaba FM, Mullarky IK, et al. Cell-mediated protection against pulmonary Yersinia pestis infection. Infection and Immunity 2005;73(November (11)):7304-10.
14. Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS, et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proceedings of the National Academy of Sciences of the United States of America 2003;100(August (16)):9458-63.
15. Demkowicz Jr WE, Littaua RA, Wang J, Ennis FA. Human cytotoxic T-cellmemory: long-lived responses to vaccinia virus. Journal of Virology 1996;70(April (4)):2627-31.
16. Williamson ED, Flick-Smith HC, Lebutt C, Rowland CA, Jones SM, Waters EL, et al. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infection and Immunity 2005;73(June (6)):3598-608.
17. Smith LA, Rusnak JM. Botulinum neurotoxin vaccines: past, present, and future. Critical Reviews in Immunology 2007;27(4):303-18.
18. Robinson HL. Nucleic acid vaccines: an overview. Vaccine 1997;15(June (8)):785-7.
19. Polo JM, Dubensky Jr TW. Virus-based vectors for human vaccine applications. Drug Discovery Today 2002;7(July (13)):719-27.
20. Papp Z, Babiuk LA, Baca-Estrada ME. The effect of pre-existing adenovirusspecific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1. Vaccine 1999;17(February (7-8)):933-43.
21. Cohen J. AIDS research. Did Merck's failed HIV vaccine cause harm? Science (New York, NY) 2007;318(November (5853)):1048-9.
22. Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Review of Vaccines 2008;7(March (2)):175-91.
23. Chong SY, Egan MA, Kutzler MA, Megati S, Masood A, Roopchard V, et al. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmidDNAvaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Vaccine 2007;25(June (26)):4967-82.
24. Boyer JD, Robinson TM, Kutzler MA, Vansant G, Hokey DA, Kumar S, et al. Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proceedings of the National Academy of Sciences of the United States of America 2007;104(November (47)):18648-53.
25. Wang S, Zhang C, Zhang L, Li J, Huang Z, Lu S. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 2008;26(April (17)):2100-10.
26. Jones S, Evans K, McElwaine-Johnn H, Sharpe M, Oxford J, Lambkin-Williams R, et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 2009;27(April (18)):2506-12.
27. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, et al. Crosssubtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008;26(July (31)):3947-57.
28. Barouch DH, McKay PF, Sumida SM, Santra S, Jackson SS, Gorgone DA, et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. Journal of Virology 2003;77(August (16)): 8729-35.
29. Grabenstein JD. Vaccines: countering anthrax: vaccines and immunoglobulins. Clinical Infectious Diseases 2008;46(January (1)):129-36.
30. Brey RN. Molecular basis for improved anthrax vaccines. Advanced Drug Delivery Reviews 2005;57(June (9)):1266-92.
31. Herrmann JE, Wang S, Zhang C, Panchal RG, Bavari S, Lyons CR, et al. Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization. Vaccine 2006;24(July (31-32)):5872-80.
32. Little SF. Anthrax vaccines: a development update. BioDrugs 2005;19(4):233-45.
33. Skoble J, Beaber JW, Gao Y, Lovchik JA, Sower LE, Liu W, et al. Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax. Infection and Immunity 2009;77(April (4)):1649-63.
34. Osorio M, Wu Y, Singh S, Merkel TJ, Bhattacharyya S, Blake MS, et al. Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge. Infection and Immunity 2009;77(April (4)):1475-82.
35. Gauthier YP, Tournier JN, Paucod JC, Corre JP, Mock M, Goossens PL, et al. Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax. Infection and Immunity 2009;77(March (3)):1197-207.
36. Trollet C, Pereira Y, Burgain A, Litzler E, Mezrahi M, Seguin J, et al. Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer. Infection and Immunity 2009;77(May (5)):2221-9.
37. Yu YZ, Zhang SM, Sun ZW, Wang S, Yu WY. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A. Vaccine 2007;25(December (52)):8843-50.
38. Baldwin MR, Tepp WH, Przedpelski A, Pier CL, Bradshaw M, Johnson EA, et al. Subunit vaccine against the seven serotypes of botulism. Infection and Immunity 2008;76(March (3)):1314-8.
39. Jones RG, Liu Y, Rigsby P, Sesardic D. An improved method for development of toxoid vaccines and antitoxins. Journal of Immunological Methods 2008;337(August (1)):42-8.
40. Xu Q, Pichichero ME, Simpson LL, Elias M, Smith LA, Zeng M. An adenoviral vector-based mucosal vaccine is effective in protection against botulism. Gene Therapy 2009;16(March (3)):367-75.
41. Zeng M, Xu Q, Elias M, Pichichero ME, Simpson LL, Smith LA. Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine 2007;25(October (43)):7540-8.
42. Titball RW, Williamson ED. Vaccination against bubonic and pneumonic plague. Vaccine 2001;19(July (30)):4175-84.
43. Titball RW, Williamson ED. Yersinia pestis (plague) vaccines. Expert Opinion on Biological Therapy 2004;4(June (6)):965-73.
44. Chichester JA, Musiychuk K, Farrance CE, Mett V, Lyons J, Mett V, et al. A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague. Vaccine 2009;27(May (25-26)):3471-4.
45. Leary SE, Griffin KF, Garmory HS, Williamson ED, Titball RW. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague. Microbial Pathogenesis 1997;23(September (3)):167-79.
46. Wang S, Heilman D, Liu F, Giehl T, Joshi S, Huang X, et al. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine 2004;22(September (25-26)): 3348-57.
47. Wang S, Joshi S, Mboudjeka I, Liu F, Ling T, Goguen JD, et al. Relative immunogenicity and protection potential of candidate Yersinia Pestis antigens against lethal mucosal plague challenge in Balb/C mice. Vaccine 2008;26(March (13)):1664-74.
48. Conlan JW. Vaccines against Francisella tularensis-past, present and future. Expert Review of Vaccines 2004;3(June (3)):307-14.
49. Bitsaktsis C, Rawool DB, Li Y, Kurkure NV, Iglesias B, Gosselin EJ. Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis. Journal of Immunology 2009;182(April (8)):4899-909.
50. Lavine CL, Clinton SR, Angelova-Fischer I, Marion TN, Bina XR, Bina JE, et al. Immunization with heat-killed Francisella tularensis LVS elicits protective antibody-mediated immunity. European Journal of Immunology 2007;37(November (11)):3007-20.
51. Fortier AH, Slayter MV, Ziemba R, Meltzer MS, Nacy CA. Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infection and Immunity 1991;59(September (9)):2922-8.
52. El Sahly HM, Atmar RL, Patel SM, Wells JM, Cate T, Ho M, et al. Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine 2009;27(August (36)):4905-11.
53. Gregory SH, Mott S, Phung J, Lee J, Moise L, McMurry JA, et al. Epitope-based vaccination against pneumonic tularemia. Vaccine 2009;(July).
54. Sjostedt A, Sandstrom G, Tarnvik A. Humoral and cell-mediated immunity in mice to a 17-kilodalton lipoprotein of Francisella tularensis expressed by Salmonella typhimurium. Infection and Immunity 1992;60(July (7)):2855-62.
55. Dreisbach VC, Cowley S, Elkins KL. Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon. Infection and Immunity 2000;68(April (4)):1988-96.
56. Huntley JF, Conley PG, Rasko DA, Hagman KE, Apicella MA, Norgard MV. Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. Infection and Immunity 2008;76(August (8)):3664-71.
57. Hoover DL, Crawford RM, Van De Verg LL, Izadjoo MJ, Bhattacharjee AK, Paranavitana CM, et al. Protection of mice against brucellosis by vaccination with Brucella melitensis WR201(16MDeltapurEK). Infection and Immunity 1999;67(November (11)):5877-84.
58. Estevan M, Gamazo C, Grillo MJ, Del Barrio GG, Blasco JM, Irache JM. Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice. Vaccine 2006;24(May (19)):4179-87.
59. Vemulapalli R, Contreras A, Sanakkayala N, Sriranganathan N, Boyle SM, Schurig GG. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice. Veterinary Microbiology 2004;102(September (3-4)):237-45.
60. Dieterich RA, Deyoe BL, Morton JK. Effects of killed Brucella abortus strain 45/20 vaccine on reindeer later challenge exposed with Brucella suis type 4. American Journal of Veterinary Research 1981;42(January (1)):131-4.
61. Arenas-Gamboa AM, Ficht TA, Kahl-McDonaghMM, Rice-Ficht AC. Immunization with a single dose of a microencapsulated Brucella melitensis mutant enhances protection against wild-type challenge. Infection and Immunity 2008;76(June (6)):2448-55.
62. Yu DH, Hu XD, Cai H. A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against Brucella abortus 2308 by inducing specific CTL responses. DNA and Cell Biology 2007;26(June (6)):435-43.
63. Luo D, Ni B, Li P, Shi W, Zhang S, Han Y, et al. Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice. Infection and Immunity 2006;74(May (5)): 2734-41.
64. Cassataro J, Estein SM, Pasquevich KA, Velikovsky CA, de la Barrera S, Bowden R, et al. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection. Infection and Immunity 2005;73(December (12)):8079-88.
65. Harms JS, Durward MA, Magnani DM, Splitter GA. Evaluation of recombinant invasive, non-pathogenic Eschericia coli as a vaccine vector against the intracellular pathogen, Brucella. Journal of Immune Based Therapies and Vaccines 2009;7:1.
66. Neeson BN, Clark GC, Atkins HS, Lingard B, Titball RW. Analysis of protection afforded by a Clostridium perfringens alpha-toxoid against heterologous clostridial phospholipases C. Microbial Pathogenesis 2007;43(October (4)):161-5.
67. Williamson ED, Titball RW. A genetically engineered vaccine against the alpha-toxin of Clostridium perfringens protects mice against experimental gas gangrene. Vaccine 1993;11(September (12)):1253-8.
68. Stevens DL, Titball RW, Jepson M, Bayer CR, Hayes-Schroer SM, Bryant AE. Immunization with the C-Domain of alpha -Toxin prevents lethal infection, localizes tissue injury, and promotes host response to challenge with Clostridium perfringens. The Journal of Infectious Diseases 2004;190(August (4)):767-73.
69. Zekarias B, Mo H, Curtiss 3rd R. Recombinant attenuated Salmonella enterica serovar typhimurium expressing the carboxy-terminal domain of alpha toxin from Clostridium perfringens induces protective responses against necrotic enteritis in chickens. Clinical and Vaccine Immunology 2008;15(May (5)):805-16.
70. Richards AL. Rickettsial vaccines: the old and the new. Expert Review of Vaccines 2004;3(October (5)):541-55.
71. Sumner JW, Sims KG, Jones DC, Anderson BE. Protection of guineapigs from experimental Rocky Mountain spotted fever by immunization with baculovirus-expressed Rickettsia rickettsii rOmpA protein. Vaccine 1995;13(January (1)):29-35.
72. Clements ML, Wisseman Jr CL, Woodward TE, Fiset P, Dumler JS, McNamee W, et al. Reactogenicity, immunogenicity, and efficacy of a chick embryo cellderived vaccine for Rocky Mountain spotted fever. The Journal of Infectious Diseases 1983;148(November (5)):922-30.
73. Dumler JS, Wisseman Jr CL, Fiset P, Clements ML. Cell-mediated immune responses of adults to vaccination, challenge with Rickettsia rickettsii, or both. The American Journal of Tropical Medicine and Hygiene 1992;46(February (2)):105-15.
74. Coker C, Majid M, Radulovic S. Development of Rickettsia prowazekii DNA vaccine: cloning strategies. Annals of the New York Academy of Sciences 2003;990:757-64.
75. Wisseman Jr CL. Concepts of louse-borne typhus control in developing countries: the use of the living attenuated E strain typhus vaccine in epidemic and endemic situations. Advances in Experimental Medicine and Biology 1972;31(0):97-130.
76. Mason RA, Wenzel RP, Seligmann Jr EB, Ginn RK. A reference, inactivated, epidemic typhus vaccine: clinical trials in man. Journal of Biological Standardization 1976;4(3):217-24.
77. Greenberg RN, Kennedy JS, Clanton DJ, Plummer EA, Hague L, Cruz J, et al. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet 2005;365(January-February (9457)):398-409.
78. Ravanfar P, Satyaprakash A, Creed R, Mendoza N. Existing antiviral vaccines. Dermatologic Therapy 2009;22(March-April (2)):110-28.
79. Kennedy RB, Ovsyannikova IG, Jacobson RM, Poland GA. The immunology of smallpox vaccines. Current Opinion in Immunology 2009;21(June (3)):314-20.
80. Sakhatskyy P, Wang S, Zhang C, Chou TH, Kishko M, Lu S. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. Virology 2008;371(February (1)):98-107.
81. Sakhatskyy P, Wang S, Chou TH, Lu S. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology 2006;355(November (2)):164-74.
82. Jacobs BL, Langland JO, Kibler KV, Denzler KL, White SD, Holechek SA, et al. Vaccinia virus vaccines: past, present and future. Antiviral Research 2009;(June).
83. Artenstein AW. Newgeneration smallpox vaccines: a review of preclinical and clinical data. Reviews in Medical Virology 2008;18(July-August (4)):217-31.
84. Bielinska AU, Chepurnov AA, Landers JJ, Janczak KW, Chepurnova TS, Luker GD, et al.Anovel, killed-virus nasal vaccinia virus vaccine. Clinical and Vaccine Immunology 2008;15(February (2)):348-58.
85. Cho HW, Howard CR, Lee HW. Review of an inactivated vaccine against hantaviruses. Intervirology 2002;45(4-6):328-33.
86. Hjelle B. Vaccines against hantaviruses. Expert Review of Vaccines 2002;1(October (3)):373-84.
87. Yamanishi K, Tanishita O, Tamura M, Asada H, Kondo K, Takagi M, et al. Development of inactivated vaccine against virus causing haemorrhagic fever with renal syndrome. Vaccine 1988;6(June (3)):278-82.
88. Maes P, Clement J, Van Ranst M. Recent approaches in hantavirus vaccine development. Expert Review of Vaccines 2009;8(January (1)):67-76.
89. Hooper JW, Custer DM, Smith J, Wahl-Jensen V. Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates. Virology 2006;347(March (1)):208-16.
90. Schmaljohn CS, Hasty SE, Dalrymple JM. Preparation of candidate vacciniavectored vaccines for haemorrhagic fever with renal syndrome. Vaccine 1992;10(1):10-3.
91. Sohn YM, Rho HO, Park MS, Kim JS, Summers PL. Primary humoral immune responses to formalin inactivated hemorrhagic fever with renal syndrome vaccine (Hantavax): consideration of active immunization in South Korea. Yonsei Medical Journal 2001;42(June (3)):278-84.
92. Maes P, Keyaerts E, Bonnet V, Clement J, Avsic-Zupanc T, Robert A, et al. Truncated recombinant Dobrava hantavirus nucleocapsid proteins induce strong, long-lasting immune responses in mice. Intervirology 2006;49(5):253-60.
93. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000;408(November (6812)):605-9.
94. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. Journal of Virology 2003;77(January (1)):799-803.
95. Bukreyev A, Marzi A, Feldmann F, Zhang L, Yang L, Ward JM, et al. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology 2009;383(January (2)):348-61.
96. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. The Journal of Infectious Diseases 2007;196(November (Suppl. 2)):S430-7.
97. Yang C, Ye L, Compans RW. Protection against filovirus infection: virus-like particle vaccines. Expert Review of Vaccines 2008;7(April (3)):333-44.
98. Hevey M, Negley D, Geisbert J, Jahrling P, Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology 1997;239(December (1)):206-16.
99. Hevey M, Negley D, VanderZanden L, Tammariello RF, Geisbert J, Schmaljohn C, et al. Marburg virus vaccines: comparing classical and new approaches. Vaccine 2001;20(November (3-4)):586-93.
100. Sheets RL, Stein J, Bailer RT, Koup RA, Andrews C, Nason M, et al. Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines againsthumanimmunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene inserts. Journal of Immunotoxicology 2008;5(July (3)):315-35.
101. Daddario-DiCaprio KM, Geisbert TW, Stroher U, Geisbert JB, Grolla A, Fritz EA, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006;367(April (9520)):1399-404.
102. Pittman PR, Liu CT, Cannon TL, Makuch RS, Mangiafico JA, Gibbs PH, et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 1999;18(August (1-2)):181-9.
103. Assaad F, Davies FG, Eddy GA, El Karamany R, Meegan JM, Ozawa Y, et al. The use of veterinary vaccines for prevention and control of Rift Valley fever: memorandum from aWHO/FAO meeting. Bulletin of the World Health Organization 1983;61(2):261-8.
104. Caplen H, Peters CJ, Bishop DH. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. The Journal of General Virology 1985;66(Pt 10):2271-7.
105. Schmaljohn CS, Parker MD, Ennis WH, Dalrymple JM, Collett MS, Suzich JA, et al. Baculovirus expression of theMgenome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology 1989;170(May (1)):184-92.
106. Gorchakov R, Volkova E, Yun N, Petrakova O, Linde NS, Paessler S, et al. Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins. Virology 2007;366(September (1)):212-25.
107. Lagerqvist N, Naslund J, Lundkvist A, Bouloy M, Ahlm C, Bucht G. Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs. Virology Journal 2009;6:6.
108. Naslund J, Lagerqvist N, Habjan M, Lundkvist A, Evander M, Ahlm C, et al. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology 2009;385(March (2)):409-15.
109. Fine DL, Roberts BA, Teehee ML, Terpening SJ, Kelly CL, Raetz JL, et al. Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses. Vaccine 2007;25(February (10)):1868-76.
110. Dupuy LC, Locher CP, Paidhungat M, Richards MJ, Lind CM, Bakken R, et al. Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine. Vaccine 2009;27(June (31)):4152-60.
111. Pittman PR, Makuch RS, Mangiafico JA, Cannon TL, Gibbs PH, Peters CJ. Longterm duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 1996;14(March (4)):337-43.
112. Edelman R, Ascher MS, Oster CN, Ramsburg HH, Cole FE, Eddy GA. Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C-84). The Journal of Infectious Diseases 1979;140(November (5)):708-15.
113. Bennett AM, Phillpotts RJ, Perkins SD, Jacobs SC, Williamson AD. Gene gun mediated vaccination is superior to manual delivery for immunisation with DNAvaccines expressing protective antigens from Yersinia pestis or Venezuelan Equine Encephalitis virus. Vaccine 1999;18(November (7-8)):588-96.
114. Hodgson LA, Ludwig GV, Smith JF. Expression, processing, and immunogenicity of the structural proteins of Venezuelan equine encephalitis virus from recombinant baculovirus vectors. Vaccine 1999;17(March (9-10)):1151-60.
115. Kinney RM, Esposito JJ, Mathews JH, Johnson BJ, Roehrig JT, Barrett AD, et al. Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge. Journal of Virology 1988;62(December (12)):4697-702.
116. Geeraedts F, Bungener L, Pool J, ter Veer W, Wilschut J, Huckriede A. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza and Other Respiratory Viruses 2008;2(March (2)):41-51.
117. Alsharifi M, Furuya Y, Bowden TR, Lobigs M, Koskinen A, Regner M, et al. Intranasal flu vaccine protective against seasonal and H5N1 avian influenza infections. PloS One 2009;4(4):e5336.
118. Wang S, Parker C, Taaffe J, Solorzano A, Garcia-Sastre A, Lu S. Heterologous HA DNAvaccine prime-inactivated influenza vaccine boost is more effective than usingDNAor inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 2008;26(July (29-30)):3626-33.
119. WangS, Taaffe J, Parker C, Solorzano A, Cao H, Garcia-Sastre A, et al. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. Journal of Virology 2006;80(December (23)):11628-37.
120. Vajo Z, Kosa L, Visontay I, Jankovics M, Jankovics I. Inactivated whole virus influenza A (H5N1) vaccine. Emerging Infectious Diseases 2007;13(May (5)):807-8.
121. Ehrlich HJ, Muller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. The New England Journal of Medicine 2008;358(June (24)):2573-84.
122. Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL, et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 2007;297(April (14)):1577-82.
123. Haynes JR. Influenza virus-like particle vaccines. Expert Review of Vaccines 2009;8(April (4)):435-45.
124. Greenwood DL, Dynon K, Kalkanidis M, Xiang S, Plebanski M, Scheerlinck JP. Vaccination against foot-and-mouth disease virus using peptides conjugated to nano-beads. Vaccine 2008;26(May (22)):2706-13.
125. Niborski V, Li Y, Brennan F, Lane M, Torche AM, Remond M, et al. Efficacy of particle-based DNA delivery for vaccination of sheep against FMDV. Vaccine 2006;24(November (49-50)):7204-13.
126. Barteling SJ, Woortmeyer R. Formaldehyde inactivation of foot-and-mouth disease virus. Conditions for the preparation of safe vaccine. Archives of Virology 1984;80(2-3):103-17.
127. Amadori M, Barei S, Melegari M, Panina GF. Safety and efficacy of foot-andmouthdisease vaccines containing endonuclease-inactivated virions. Vaccine 1987;5(September (3)):219-22.
128. Mason PW, Piccone ME, McKenna TS, Chinsangaram J, Grubman MJ. Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate. Virology 1997;227(January (1)):96-102.
129. Ishimaru D, Sa-Carvalho D, Silva JL. Pressure-inactivated FMDV: a potential vaccine. Vaccine 2004;22(June (17-18)):2334-9.
130. Zheng M, Jin N, Zhang H, Jin M, Lu H, Ma M, et al. Construction and immunogenicity of a recombinant fowlpox virus containing the capsid and 3C protease coding regions of foot-and-mouth disease virus. Journal of Virological Methods 2006;136(September (1-2)):230-7.
131. Du Y, Jiang P, Li Y, He H, Jiang W, Wang X, et al. Immune responses of two recombinant adenoviruses expressing VP1 antigens of FMDV fused with porcine granulocyte macrophage colony-stimulating factor. Vaccine 2007;25(November (49)):8209-19.
132. Li Z, Yi Y, Yin X, Zhang Z, Liu J. Expression of foot-and-mouth disease virus capsid proteins in silkworm-baculovirus expression system and its utilization as a subunit vaccine. PloS One 2008;3(5):e2273.
133. Qian P, Li XM, Jin ML, Peng GQ, Chen HC. An approach to a FMD vaccine based on genetic engineered attenuated pseudorabies virus: one experiment using VP1 gene alone generates an antibody responds on FMD and pseudorabies in swine. Vaccine 2004;22(June (17-18)):2129-36.
134. Stott JL, Barber TL, Osburn BI. Immunologic response of sheep to inactivated and virulent bluetongue virus. American Journal of Veterinary Research 1985;46(May (5)):1043-9.
135. Bhanuprakash V, Indrani BK, Hosamani M, Balamurugan V, Singh RK. Bluetongue vaccines: the past, present and future. Expert Review of Vaccines 2009;8(February (2)):191-204.
136. Roy P, Boyce M, Noad R. Prospects for improved bluetongue vaccines. Nature Reviews 2009;7(February (2)):120-8.
137. Campbell CH. Immunogenicity of bluetongue virus inactivated by gamma irradiation. Vaccine 1985;3(December (5)):401-6.
138. Boone JD, Balasuriya UB, Karaca K, Audonnet JC, Yao J, He L, et al. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 2007;25(January (4)):672-8.
139. Zheng YZ, Greenfield PF, Reid S. Optimized production of recombinant bluetongue core-like particles produced by the baculovirus expression system. Biotechnology and Bioengineering 1999;65(December (5)): 600-4.
140. Roy P. Genetically engineered particulate virus-like structures and their use as vaccine delivery systems. Intervirology 1996;39(1-2):62-71.
141. Roy P. Multiple gene expression in baculovirus system. Third generation vaccines for bluetongue disease and African horsesickness disease. Annals of the New York Academy of Sciences 1996;791(July):318-32.
142. Boyce M, Celma CC, Roy P. Development of reverse genetics systems for bluetongue virus: recovery of infectious virus from synthetic RNA transcripts. Journal of Virology 2008;82(September (17)):8339-48.